Yu, P.; Shang, C.; Liu, Z.; Li, Y.; He, T.; Xue, Y.; Lin, J.; Li, Y.; Wu, Y.; Liu, T.;
et al. High Co-Expression of GPAT4 and SLC7A11 as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer. Biomedicines 2025, 13, 1664.
https://doi.org/10.3390/biomedicines13071664
AMA Style
Yu P, Shang C, Liu Z, Li Y, He T, Xue Y, Lin J, Li Y, Wu Y, Liu T,
et al. High Co-Expression of GPAT4 and SLC7A11 as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer. Biomedicines. 2025; 13(7):1664.
https://doi.org/10.3390/biomedicines13071664
Chicago/Turabian Style
Yu, Ping, Chunliang Shang, Zhongyu Liu, Yuan Li, Tianhui He, Yuan Xue, Jian Lin, Yuan Li, Yu Wu, Tong Liu,
and et al. 2025. "High Co-Expression of GPAT4 and SLC7A11 as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer" Biomedicines 13, no. 7: 1664.
https://doi.org/10.3390/biomedicines13071664
APA Style
Yu, P., Shang, C., Liu, Z., Li, Y., He, T., Xue, Y., Lin, J., Li, Y., Wu, Y., Liu, T., & Guo, H.
(2025). High Co-Expression of GPAT4 and SLC7A11 as a Predictor of Platinum Resistance and Poor Prognosis in Patients with Epithelial Ovarian Cancer. Biomedicines, 13(7), 1664.
https://doi.org/10.3390/biomedicines13071664